2-deoxy-2-[F-18]fluoro-D-glucose - Positron emission tomography/computed tomography imaging evaluation of esophageal cancer

Molecular Imaging and Biology

Volumn 8, Issue 3, 2006, Pages 193-200

  Jadvar, Hossein ^a   Henderson, Robert W ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Esophageal cancer; FDG; PET CT

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERMETABOLISM; IMAGE ANALYSIS; LIPID LIVER LEVEL; LUNG NODULE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SAMPLING; TREATMENT PLANNING; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33746919016     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-006-0036-5     Document Type: Article

References (60)

1. Yang PC, Davis S (1988) Incidence of cancer of the esophagus in the US by histology types. Cancer 61(3):612-617
2. Younes M, Henson DE, Ertan A, Miller CC (2002) Incidence and survival trends of esophageal carcinoma in the United States: Racial and gender differences by histological type. Scand J Gastroenterol 37(12):1359-1365
3. Korst RJ, Altorki NK (2004) Imaging for esophageal tumors. Thorac Surg Clin 14:61-69
4. Kato H, Takita J, Miyazaki T, et al. (2003) Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal in esophageal squamous cell carcinoma. Anticancer Res 23:3263-3272
5. Menzel CH, Dobert N, Rieker O, et al. (2003) 18F-deoxyglucose PET for the staging of esophageal cancer: Influence of histopathological subtype and tumor grading. Nuklearmediziner 42:90-93
6. Tohma T, Okazumi S, Makino H, et al. (2005) Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepato-gastroenterol 52:486-490
7. Wallace MB, Nietert PJ, Earle C, et al. (2002) An analysis of multiple staging management strategies for carcinoma of the esophagus: Computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg 74:1026-1032
8. Flamen P, Lerut A, van Cutsem E, et al. (2000) The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 120:1085-1092
9. Townsend DW (2004) From 3-D positron emission tomography to 3-D positron emission tomography/computed tomography: What did we learn? Mol Imaging Biol 6(5):275-290
10. Rice TW (2000) Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg Clin North Am 10:471-485
11. Kubota R, Yamada S, Kubota K, et al. (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33(11):1972-1980
12. Luketich JD, Schauer PR, Meltzer CC, et al. (1997) Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 64:765-769
13. Skehan SJ, Brown AL, Thompson M, et al. (2000) Imaging features of primary and recurrent esophageal cancer at FDG-PET. Radiographics 21:713-723
14. Jadvar H, Cham DK, Conti PS (2003) Diagnostic evaluation of esophageal carcinoma with [F-18]-FDG-PET/CT. Mol Imaging Biol 5(3):188
15. Fukunaga T, Okazumi S, Koide Y, et al. (1998) Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 39:1002-1007
16. Kato H, Kuwano H, Nakajima M, et al. (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94:921-928
17. McAteer D, Wallis F, Couper G, et al. (1999) Evaluation of 18F-FDG positron emission tomography in gastric and esophageal carcinoma. Br J Radiol 72:525-529
18. Choi JY, Lee KH, Shim YM, et al. (2000) Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG-PET. J Nucl Med 41:808-815
19. Meltzer CC, Luketich JD, Friedman D, et al. (2000) Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 25:882-887
20. Wren SM, Stijns P, Srinivas S (2002) Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 137:1001-1006
21. Himeno S, Yasuda S, Shimada H, et al. (2002) Evaluation of esophageal cancer by positron emission tomography. Jpn J Clin Oncol 32:340-346
22. Rasanen JV, Sihvo EI, Knuuti MJ (2003) Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 10:954-960
23. Heeren PA, Jager PL, Bongaerts F, et al. (2004) Detection of distant metastases in esophageal cancer with (18)F-FDG-PET. J Nucl Med 45:980-987
24. Liberale G, van Lathem JL, Gay F, et al. (2004) The role of PET scan in the preoperative management of esophageal cancer. Eur J Surg Oncol 30:942-947
25. Kato H, Miyazaki T, Nakajima M, et al. (2005) The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 103:148-156
26. Kneist W, Schreckenberger M, Bartenstein P, et al. (2003) Positron emission tomography for staging esophageal cancer: Does it lead to a different therapeutic approach? World J Surg 27:1105-1112
27. van Westreenen HL, Heeren PA, Jager PL, et al. (2003) Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol 10:1100-1105
28. Bar-Shalom R, Guralnik L, Tsalic M, et al. (2006) The additional value of PET/CT over PET in FDG imaging of esophageal cancer. Eur J Nucl Med Mol Imaging (in press)
29. Flanagan FL, Dehdashti F, Siegel BA, et al. (1997) Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168:417-424
30. Kole AC, Plukker JT, Nieweg OE, Vaalburg W (1998) Positron emission tomography for staging of esophageal and gastroesophageal malignancy. Br J Cancer 78:521-527
31. Rankin SC, Taylor H, Cook GJ, Mason R (1998) Computed tomography and positron emission tomography in the pre-operative staging of esophageal carcinoma. Clin Radiol 53:659-665
32. Luketich JD, Friedman DM, Weigel TL (1999) Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 68:1133-1136
33. Flamen P, Lerut A, van Cutsem E, et al. (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18:3202-3210
34. Yoon YC, Lee KS, Shim YM, et al. (2003) Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG-PET for presurgical detection prospective study. Radiology 227:764-770
35. Sihvo EI, Rasanen JV, Knuuti MJ, et al. (2004) Adenocarcinoma of the esophagus and the esophagogastric junction: Positron emission tomography improves staging and prediction of survival in distant but not in locoregional disease. J Gastrointest Surg 8:988-996
36. Kato H, Miyazaki T, Nakajima M, et al. (2004) Value of positron emission tomography in the diagnosis of recurrent esophageal carcinoma. Br J Surg 91:1004-1009
37. Kim K, Park SJ, Kim BT, et al. (2001) Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg 71:290-294
38. Kneist W, Schreckenberger M, Bartenstein P, et al. (2004) Prospective evaluation of positron emission tomography in the preoperative staging of esophageal carcinoma. Arch Surg 139:1043-1049
39. Larson SM, Schoder H, Yeung H (2004) Positron emission tomography/ computerized tomography functional imaging of esophageal and colorectal cancer. Cancer J 10:243-250
40. van Westreenen HL, Westerterp M, Bossuyt PM, et al. (2004) Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22:3805-3812
41. Yeung HW, Macapinlac HA, Mazumdar M, et al. (1999) FDG-PET in esophageal cancer. Incremental value over computed tomography. Clin Positron Imaging 2:255-260
42. Imdahl A, Hentschel M, Kleimaier M, et al. (2004) Impact of FDG-PET for staging of esophageal cancer. Langenbecks Arch Surg 389:283-288
43. van Westreenen HL, Heeren PA, van Dullemen HM, et al. (2005) Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations. J Gastrointest Surg 9:44-61
44. Ichiya Y, Kuwabara Y, Otsuka M, et al. (1991) Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 32:1655-1660
45. Couper GW, McAteer D, Wallis F, et al. (1998) Detection of response to chemotherapy using positron emission tomography in patients with esophageal and gastric cancer. Br J Surg 85:1403-1406
46. Kato H, Kuwano H, Nakajima M, et al. (2002) Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184:279-283
47. Arslan N, Miller TR, Dehdashti F, et al. (2002) Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 4:301-310
48. Brink I, Hentschel M, Bley TA, et al. (2004) Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol 30:544-550
49. Cerfolio RJ, Bryant AS, Ohja B, et al. (2005) The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 129:1232-1241
50. Song SY, Kim JH, Ryu JS, et al. (2005) FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 63:1053-1059
51. Konski A, Doss M, Milestone B, et al. (2005) The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys 61:1123-1128
52. Swisher SG, Maish M, Erasmus JJ, et al. (2004) Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78:1152-1160
53. Vrieze O, Haustermans K, De Wever W, et al. (2004) Is there a role for FDG-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 73:269-275
54. Weider HA, Brucher BL, Zimmerman F (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22:900-908
55. Arslan N, Miller TR, Dehdashti F, et al. (2002) Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-d-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 4(4):301-310
56. Brucher BL, Weber W, Bauer M, et al. (2001) Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography. Ann Surg 233:300-309
57. Flamen P, van Cutsem E, Lerut A, et al. (2002) Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced esophageal cancer. Ann Oncol 13:361-368
58. Downey RJ, Akhurst T, Ilson D, et al. (2003) Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial. J Clin Oncol 21:428-432
59. Flamen P, Lerut T, Haustermans K, et al. (2004) Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imaging 48:96-108
60. Choi JY, Jang HJ, Shim YM, et al. (2004) 18F-FDG-PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: Prognostic implications. J Nucl Med 45:1843-1850